Activity of moxifloxacin against mycobacteria

Journal of Antimicrobial Chemotherapy

Volumn 44, Issue 3, 1999, Pages 393-395

  Gillespie, S H ^a   Billington, O ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; ISONIAZID; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM FORTUITUM; MYCOBACTERIUM INTRACELLULARE AVIUM; MYCOBACTERIUM KANSASII; MYCOBACTERIUM TUBERCULOSIS;

4-QUINOLONES; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; QUINOLINES;

EID: 0032870624     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/44.3.393     Document Type: Article

References (12)

1. Raviglione, M. C., Snider, D. E. & Kochi, A. (1995). Global epidemiology of tuberculosis: morbidity and mortality of a worldwide epidemic. Journal of the American Medical Association 273, 220-6.
2. Gillespie, S. H. & Kennedy, N. (1998). Fluoroquinolones; a new treatment for tuberculosis? International Journal of Tuberculosis and Lung Diseases 2, 265-71.
3. Yew, W. W., Piddock, L. J. V., Li, M. S. K., Lyon, D., Chan, C. Y. & Cheng, A. F. B. (1994). In-vitro activity of quinolones and macrolides against mycobacteria. Journal of Antimicrobial Chemotherapy 34, 343-51.
4. Woodcock, J. M., Andrews, J. M., Boswell, F. J., Brenwald, N. P. & Wise, R. (1997). In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrobial Agents and Chemotherapy 41, 101-6.
5. Collins, C. G., Grange, J. M. & Yates, M. D. (1997). Tuberculosis Bacteriology Organization and Practice, 2nd edn. Butterworth Heinemann, Oxford, UK.
6. Rastogi, N., Goh, K. S., Bryskier, A. & Devallois, A. (1996). Spectrum of activity of levofloxacin against non-tuberculosis mycobacteria and its activity against the M. avium complex in combination with ethambutol, rifampicin, roxithromycin, amikacin and clofazimine. Antimicrobial Agents and Chemotherapy 40, 2483-7.
7. th edn (Balows, A., Hansler, W. J., Herrmann, K., Isenberg, H. D. & Shadomy, H. J., Eds), pp. 1138-52. American Society for Microbiology, Washington, DC.
8. Kennedy, N., Berger, L., Curram, J., Fox, R., Gutmann, J., Kisyombe, G. M. et al. (1996). Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis. Clinical Infectious Diseases 22, 827-33.
9. Jindani, A., Aber, V. R., Edwards, D. A. & Mitchison, D. A. (1980). The early bactericidal activity of drugs in patients with pulmonary tuberculosis. American Review of Respiratory Disease 121, 939-49.
10. Sirgel, F. A., Botha, F. J., Parkin, D. P., van de Wal, B. W., Schall, R., Donald, P. R. et al. (1997). The early bactericidal activity of ciprofloxacin in patients with pulmonary tuberculosis. American Journal of Respiratory and Critical Care Medicine 156, 901-5.
11. Stass, H. H., Kubitza, D. & Schükly, U. (1997). BAY 12-8039 a new methoxyquinolone: pharmacokinetics, safety, and tolerability of single ascending intraveneous doses in healthy male volunteers. In Program and Abstracts of the Thirty-Seventh Interscience Congress on Antimicrobial Agents and Chemotherapy, Toronto, 1997. Abstract F-153. p. 172. American Society for Microbiology, Washington, DC.
12. Gross, W. M., Vadney, F. S., Ladutko, L., Bonato, D. A., Campbell, S. I. (1997). In vitro activity of BAY 12-8039, a new 8-methoxyquinolone, against mycobacteria. In Program and Abstracts of the Thirty-Seventh Interscience Congress on Antimicrobial Agents and Chemotherapy, Toronto, 1997. Abstract F-144. p. 170.